TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 22729610

Group type: EXPERIMENTAL
Intervention: Hypoxic exercise (FIO(2) = 0.12)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Normoxic exercise (FIO(2) = 0.21)
Number of subjects: 8
Study: 21743410

Group type: EXPERIMENTAL
Intervention: Test mouth-rinse containing chlorhexidine and cetylpyridinium chloride
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36
Study: 19779705

Group type: EXPERIMENTAL
Intervention: Oral cyclosporin A
Number of subjects: 16

Group type: COMPARATOR
Intervention: ART only (Control)
Number of subjects: 16
Study: 16427198

Group type: EXPERIMENTAL
Intervention: Deep pain
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Superficial pain
Number of subjects: 0
Study: 15273337

Group type: EXPERIMENTAL
Intervention: Gadolinium-enhanced MR imaging at 3 weeks
Number of subjects: 54

Group type: COMPARATOR
Intervention: Biopsy at 6 months
Number of subjects: 54
Study: 11292273

Group type: EXPERIMENTAL
Intervention: Home-based psychosocial nursing interventions (2 home visits after high psychological distress score)
Number of subjects: 433
Study: 10211006

Group type: EXPERIMENTAL
Intervention: Desflurane (3% end-expired concentration)
Number of subjects: 32

Group type: COMPARATOR
Intervention: Isoflurane (0.6% end-expired concentration)
Number of subjects: 32
Study: 7948439

Group type: EXPERIMENTAL
Intervention: Ketotifen
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (not specified what treatment)
Number of subjects: 0
Study: 2892991

Group type: EXPERIMENTAL
Intervention: Topical interferon‐beta (IFN‐beta) gel (10(5) U/g) 4 times daily applied locally during eruptions (about 10 days)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 30566636

Group type: EXPERIMENTAL
Intervention: 4 ID PEP booster doses of 0.1 mL PCEV
Number of subjects: 303

Group type: COMPARATOR
Intervention: 2 ID PEP booster doses of 0.1 mL PCEV
Number of subjects: 303

Group type: EXPERIMENTAL
Intervention: Primary vaccination with 2 ID doses of 0.1 mL PCEV
Number of subjects: 303
Study: 29266260

Group type: EXPERIMENTAL
Intervention: Acupressure bands
Number of subjects: 187

Group type: COMPARATOR
Intervention: Sham bands
Number of subjects: 187
Study: 26782228

Group type: EXPERIMENTAL
Intervention: 20 mg of BioPQQ™ per day for 12 weeks
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study: 24854829

Group type: EXPERIMENTAL
Intervention: Olfactory (SMELL: n = 8)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Gustatory (TASTE: n = 10)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Olfactory+gustatory (SMELL+TASTE: n = 9)
Number of subjects: 27
Study: 22569211

Group type: EXPERIMENTAL
Intervention: Tobacco Tactics website
Number of subjects: 184

Group type: COMPARATOR
Intervention: 1-800-QUIT-NOW telephone line
Number of subjects: 184
Study: 21155437

Group type: EXPERIMENTAL
Intervention: Rocuronium group (n = 30) received PB with a local anesthetic mixture (Lidocaine 2% + Bupivacaine 0.5%) to which was added 0.06 mg/Kg of rocuronium
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (n = 30) received PB with the same mixture to which was added saline
Number of subjects: 60
Study: 17289893

Group type: EXPERIMENTAL
Intervention: PV701 (24x10(9) plaque‐forming units/m2 for the first dose, 120x10(9) plaque‐forming units/m2 for doses 2 to 6)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: PV701
Number of subjects: 18
Study: 16332657

Group type: EXPERIMENTAL
Intervention: High calcium (1259 +/- 9 mg/d), high dairy (high/high)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: High calcium (1259 +/- 9 mg/d), low dairy (high/low)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Low calcium (349 +/- 8 mg/d), low dairy (low/low)
Number of subjects: 12

Group type: COMPARATOR
Intervention: High/high
Number of subjects: 12

Group type: COMPARATOR
Intervention: High/low
Number of subjects: 12

Group type: COMPARATOR
Intervention: Low/low
Number of subjects: 12
Study: 11959610

Group type: EXPERIMENTAL
Intervention: Azithromycin 10 mg/kg for 3 days
Number of subjects: 56

Group type: EXPERIMENTAL
Intervention: Azithromycin 20 mg/kg for 3 days
Number of subjects: 56
Study: 10065781

Group type: EXPERIMENTAL
Intervention: Octreotide
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Urinary FSH
Number of subjects: 12
Study: 8821274

Group type: EXPERIMENTAL
Intervention: Early range of motion training in a Walker-Boot
Number of subjects: 40

Group type: COMPARATOR
Intervention: Immobilization for 6 weeks in a plaster cast
Number of subjects: 40
Study: 2084279

Group type: EXPERIMENTAL
Intervention: Abana
Number of subjects: 50

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 50
Study: 6938019

Group type: EXPERIMENTAL
Intervention: cytoxan and 5-FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: estracyt or streptozotocin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: prednimustine and DTIC
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: cytoxan and DES combined
Number of subjects: 0

Group type: COMPARATOR
Intervention: methyl CCNU and hydroxyurea
Number of subjects: 0

Group type: COMPARATOR
Intervention: estracyt or vincristine alone or in combination
Number of subjects: 0

Group type: COMPARATOR
Intervention: cytoxan or estracyt
Number of subjects: 0
Study: 31366352

Group type: EXPERIMENTAL
Intervention: Cashew apple juice (CAJ) at 3.5 mL/kgBM/day for 4 weeks
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Cashew apple juice (CAJ)
Number of subjects: 20
Study: 27534738

Group type: EXPERIMENTAL
Intervention: Bisoprolol 5 mg once daily for 12 weeks
Number of subjects: 186

Group type: COMPARATOR
Intervention: Metoprolol CR/ZOK 47.5 mg once daily for 12 weeks
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Bisoprolol
Number of subjects: 186

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 186

Group type: COMPARATOR
Intervention: Metoprolol CR/ZOK
Number of subjects: 186
Study: 25994539

Group type: EXPERIMENTAL
Intervention: Continuation maintenance therapy with pemetrexed
Number of subjects: 0
Study: 24135831

Group type: EXPERIMENTAL
Intervention: Diltiazem 360 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Verapamil 240 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Metoprolol 100 mg
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Carvedilol 25 mg
Number of subjects: 60
Study: 23230983

Group type: EXPERIMENTAL
Intervention: Psychological absence measured at the child's 36-month birthday-related assessment
Number of subjects: 2632
Study: 19003731

Group type: EXPERIMENTAL
Intervention: Family systems therapeutic interventions
Number of subjects: 187

Group type: COMPARATOR
Intervention: Control group (treated before team training)
Number of subjects: 187
Study: 17200357

Group type: EXPERIMENTAL
Intervention: IL‐12 at 30 ng/kg with alum (group A)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: IL‐12 at 100 ng/kg with alum (group B)
Number of subjects: 60

Group type: COMPARATOR
Intervention: IL‐12 at 30 ng/kg with 250 mug GM‐CSF (group C)
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Post-vaccine immune response to MART‐1
Number of subjects: 60
Study: 15627154

Group type: EXPERIMENTAL
Intervention: 0.1% diclofenac sodium (Naclof) eye drops
Number of subjects: 26

Group type: COMPARATOR
Intervention: 1% prednisolone acetate eye suspension
Number of subjects: 26
Study: 12355941

Group type: EXPERIMENTAL
Intervention: Hormonal therapy involving intravesical instillation after transurethral resection for superficial bladder cancer
Number of subjects: 102
Study: 9747867

Group type: EXPERIMENTAL
Intervention: Combination of L-phenylalanine mustard, 5-fluorouracil, and doxorubicin (PAF)
Number of subjects: 638

Group type: COMPARATOR
Intervention: L-phenylalanine mustard plus 5-fluorouracil (PF)
Number of subjects: 638
Study: 8010083

Group type: EXPERIMENTAL
Intervention: Ofl tablets evaluated by NONMEM
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ofl tablets evaluated by standard approach
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Ofl tablets evaluated by NONMEM with sparse clinical data
Number of subjects: 12
Study: 2061447

Group type: EXPERIMENTAL
Intervention: Spot dermabrasion ('scarabrasion') on the left half of each scar
Number of subjects: 48

Group type: COMPARATOR
Intervention: Untreated right half of each scar (control)
Number of subjects: 48
Study: 347459

Group type: EXPERIMENTAL
Intervention: CPC containing mouthwash
Number of subjects: 41

Group type: COMPARATOR
Intervention: Placebo mouthwash
Number of subjects: 41
Study: 30301963

Group type: EXPERIMENTAL
Intervention: Weight Watchers® (WW) program
Number of subjects: 292

Group type: COMPARATOR
Intervention: Self-help (SH) condition
Number of subjects: 292
Study: 27630253

Group type: EXPERIMENTAL
Intervention: IncobotulinumtoxinA (IBTA) injection
Number of subjects: 50

Group type: COMPARATOR
Intervention: Saline injection (placebo)
Number of subjects: 50
Study: 25029009

Group type: EXPERIMENTAL
Intervention: SM: slow motivational songs, applied during 5 km of running
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: FM: fast and motivational songs, applied during 5 km of running
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: PM: motivational songs, applied before 5 km of running
Number of subjects: 15

Group type: EXPERIMENTAL
Intervention: CS: calm songs, applied after 5 km of running
Number of subjects: 15
Study: 23948540

Group type: EXPERIMENTAL
Intervention: Intravenous alcohol administration
Number of subjects: 32
Study: 21576654

Group type: EXPERIMENTAL
Intervention: Cardiac Rehabilitation (CR) participation (40% of cohort, 964 of 2395)
Number of subjects: 2395
Study: 19814624

Group type: EXPERIMENTAL
Intervention: 7-valent pneumococcal conjugate vaccine (7vPnC)
Number of subjects: 599

Group type: COMPARATOR
Intervention: 23-valent polysaccharide vaccine (PPV)
Number of subjects: 599
Study: 18581096

Group type: EXPERIMENTAL
Intervention: Opiate antagonists (nalmefene 50 or 100 mg/day or naltrexone 100 or 150 mg/day)
Number of subjects: 284

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 284
Study: 15024667

Group type: EXPERIMENTAL
Intervention: Endurance protocol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Moderate interval protocol
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Resistance protocol
Number of subjects: 6
Study: 11816482

Group type: EXPERIMENTAL
Intervention: 40 mg doxorubicin
Number of subjects: 465

Group type: EXPERIMENTAL
Intervention: 40 mg epirubicin
Number of subjects: 465

Group type: COMPARATOR
Intervention: No instillation
Number of subjects: 465
Study: 9839100

Group type: EXPERIMENTAL
Intervention: Treatment group A (lispro and NPH injected separately)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Treatment group B (lispro and NPH mixed in syringe)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Treatment group C (human regular insulin and NPH mixed)
Number of subjects: 12
Study: 8135432

Group type: EXPERIMENTAL
Intervention: Warm buffered lidocaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Warm lidocaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Buffered lidocaine
Number of subjects: 32

Group type: COMPARATOR
Intervention: Room-temperature unbuffered lidocaine
Number of subjects: 32
Study: 2783702

Group type: EXPERIMENTAL
Intervention: Amitriptyline (up to 75 mg/day)
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Fluoxetine (up to 40 mg/day)
Number of subjects: 12

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Alcohol (measured dose)
Number of subjects: 12
Study: 977751

Group type: EXPERIMENTAL
Intervention: One-word verbal reinforcement (VR)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lengthy verbal information feedback (IF)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 30
Study: 12014128

Group type: EXPERIMENTAL
Intervention: Electro-acupuncture treatment for 4 weeks
Number of subjects: 86

Group type: COMPARATOR
Intervention: Control group with clinical treatment plus active and/or passive functional exercise
Number of subjects: 86
Study: 31069191

Group type: EXPERIMENTAL
Intervention: Nimotuzumab plus CRT
Number of subjects: 29

Group type: COMPARATOR
Intervention: CRT alone
Number of subjects: 29
Study: 29222139

Group type: EXPERIMENTAL
Intervention: Losartan (150 mg daily)
Number of subjects: 95

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 95
Study: 26901237

Group type: EXPERIMENTAL
Intervention: Continuous infiltration of local anesthetic at the nephrostomy site
Number of subjects: 60

Group type: EXPERIMENTAL
Intervention: Local anesthetic injected only once
Number of subjects: 60

Group type: COMPARATOR
Intervention: 0.9% saline injected as a control
Number of subjects: 60
Study: 24965303

Group type: EXPERIMENTAL
Intervention: exendin(9-39)NH2 (ex9-39) intravenous infusion
Number of subjects: 10

Group type: COMPARATOR
Intervention: saline intravenous infusion
Number of subjects: 10
Study: 22364402

Group type: EXPERIMENTAL
Intervention: Long-acting methylphenidate formulation (MPH-ret)
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Immediate-release methylphenidate (MPH-IR)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 36
Study: 20585297

Group type: EXPERIMENTAL
Intervention: Very Low-Carbohydrate Diet (VLCD) (<40 g carbohydrate; n=12)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional Diet (CONV) (500 to 800 kcal; n=12)
Number of subjects: 24
Study: 17579542

Group type: EXPERIMENTAL
Intervention: Active listening and collaborative problem-solving models
Number of subjects: 2611

Group type: EXPERIMENTAL
Intervention: Quality assurance and standardized practices recommendations
Number of subjects: 2611
Study: 16376739

Group type: EXPERIMENTAL
Intervention: MCO home visits
Number of subjects: 250

Group type: EXPERIMENTAL
Intervention: Low Karnofsky Index (KI)
Number of subjects: 250

Group type: COMPARATOR
Intervention: General characteristics (age, gender, rural or urban residence, disease)
Number of subjects: 250

Group type: COMPARATOR
Intervention: Type of care at referral (chemotherapy, palliative care, or other supportive care)
Number of subjects: 250
Study: 12075144

Group type: EXPERIMENTAL
Intervention: Normal Vision (NV)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Laparoscopic Vision (LV)
Number of subjects: 11
Study: 9869235

Group type: EXPERIMENTAL
Intervention: 192Ir
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8584183

Group type: EXPERIMENTAL
Intervention: Mental scanning of visual images generated from verbal descriptions; specific sequencing of descriptions (continuous vs. discontinuous)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Quantitative model of image elaboration
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Computer program simulating mental scanning protocol
Number of subjects: 0
Study: 2765334

Group type: EXPERIMENTAL
Intervention: Midazolam + Methohexitone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Methohexitone alone
Number of subjects: 60

Group type: COMPARATOR
Intervention: Midazolam alone
Number of subjects: 60
Study: 975978

Group type: EXPERIMENTAL
Intervention: 5-percent solution of metaproterenol sulfate (Alupent)
Number of subjects: 27

Group type: COMPARATOR
Intervention: 0.5-percent solution of isoproterenol
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: metaproterenol therapy
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: metaproterenol
Number of subjects: 27
Study: 30586747

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using SAPIEN XT valve (XT-TAVR)
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR) using SAPIEN 3 valve (S3-TAVR)
Number of subjects: 3110

Group type: EXPERIMENTAL
Intervention: Transcatheter aortic valve replacement (TAVR)
Number of subjects: 3110

Group type: COMPARATOR
Intervention: Surgical aortic valve replacement (SAVR)
Number of subjects: 3110
Study: 28145956

Group type: EXPERIMENTAL
Intervention: Hallux valgus group
Number of subjects: 20
Study: 27297375

Group type: EXPERIMENTAL
Intervention: Family empowerment program (4 counselling dialogues)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Traditional care in asthma clinics
Number of subjects: 65
Study: 25060104

Group type: EXPERIMENTAL
Intervention: Reproductive health program consisting of reproductive health education, health counseling, phone monitoring, and emotional support implemented for four weeks
Number of subjects: 58

Group type: COMPARATOR
Intervention: Control group (no intervention specified)
Number of subjects: 58
Study: 22492922

Group type: EXPERIMENTAL
Intervention: Functional Fascial Taping
Number of subjects: 43

Group type: COMPARATOR
Intervention: Placebo Taping
Number of subjects: 43
Study: 19535431

Group type: EXPERIMENTAL
Intervention: Eating with a friend
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Eating with an overweight partner (friend or unfamiliar peer)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Eating with an unfamiliar peer
Number of subjects: 65
Study: 17463141

Group type: EXPERIMENTAL
Intervention: OIENS + glyc
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: OIENS
Number of subjects: 74

Group type: COMPARATOR
Intervention: Control
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 74
Study: 14695785

Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM) administered perioperatively, starting 7 days before surgery and continuing for 10 days after surgery.
Number of subjects: 49

Group type: COMPARATOR
Intervention: Control group (no cimetidine treatment).
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Cimetidine (CIM) treatment.
Number of subjects: 49
Study: 11336170

Group type: EXPERIMENTAL
Intervention: Interferon alpha alone (3 MU tiw) or in combination with ribavirin for 6-12 months
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group (age- and gender-matched)
Number of subjects: 25
Study: 9203615

Group type: EXPERIMENTAL
Intervention: Minimally invasive vein harvest technique (group 1)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Standard method (group 2)
Number of subjects: 30
Study: 7956281

Group type: EXPERIMENTAL
Intervention: Heparin (6.0 +/- 0.3 IU/kg/hr)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: PGI2 (7.7 +/- 0.7 ng/kg/min)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Both PGI2 (6.4 +/- 0.3 ng/kg/min) and Heparin (5.0 +/- 0.4 IU/kg/hr)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 46
Study: 2884759

Group type: EXPERIMENTAL
Intervention: Hemodilution (venesection and infusion of dextran 40)
Number of subjects: 1200

Group type: COMPARATOR
Intervention: Standard treatment provided by each center
Number of subjects: 1200
Study: 30441289

Group type: EXPERIMENTAL
Intervention: Fuzzy Logic Controller (FLC) for cycling performance measurement
Number of subjects: 15
Study: 27930455

Group type: EXPERIMENTAL
Intervention: 4vs4+2IW+2IEW-NO
Number of subjects: 22

Group type: EXPERIMENTAL
Intervention: 4vs4+2IW+2IEW-GK
Number of subjects: 22

Group type: COMPARATOR
Intervention: 4vs4-NO
Number of subjects: 22

Group type: COMPARATOR
Intervention: 4vs4+2IW-NO
Number of subjects: 22

Group type: COMPARATOR
Intervention: 4vs4-GK
Number of subjects: 22
Study: 25385705

Group type: EXPERIMENTAL
Intervention: Any binge eating
Number of subjects: 392

Group type: COMPARATOR
Intervention: Never binge eating
Number of subjects: 392

Group type: EXPERIMENTAL
Intervention: High-frequency binge eating
Number of subjects: 392
Study: 23157922

Group type: EXPERIMENTAL
Intervention: Ischemia Index
Number of subjects: 55
Study: 21520442

Group type: EXPERIMENTAL
Intervention: Regular physical participation (Group B)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Sedentary (Group A)
Number of subjects: 18
Study: 18067517

Group type: EXPERIMENTAL
Intervention: COPD training (endurance training at 85% of VO(2max) twice weekly for 7 weeks plus daily home-based training)
Number of subjects: 19

Group type: EXPERIMENTAL
Intervention: COPD training
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group (not specified in detail)
Number of subjects: 19
Study: 16689001

Group type: EXPERIMENTAL
Intervention: Jiangtang Bushen Recipe (JBR), one dose a day for 4 weeks
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: Jiangtang Bushen Recipe (JBR)
Number of subjects: 64

Group type: COMPARATOR
Intervention: Control group (education course, dietary treatment, and conventional hypoglycemic agent)
Number of subjects: 64
Study: 12656692

Group type: EXPERIMENTAL
Intervention: VSL#3 (450 billion lyophilized bacteria/day)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25

Group type: EXPERIMENTAL
Intervention: VSL#3
Number of subjects: 25
Study: 10720511

Group type: EXPERIMENTAL
Intervention: Combination therapy with zidovudine and didanosine with or without nevirapine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Zidovudine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Didanosine
Number of subjects: 57

Group type: EXPERIMENTAL
Intervention: Nevirapine
Number of subjects: 57
Study: 9178167

Group type: EXPERIMENTAL
Intervention: Riluzole 50 mg daily
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Riluzole 100 mg daily
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Riluzole 200 mg daily
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Riluzole (all dosages)
Number of subjects: 844

Group type: EXPERIMENTAL
Intervention: Riluzole Early Access Program
Number of subjects: 844
Study: 8499208

Group type: EXPERIMENTAL
Intervention: Propofol (total dose 3.2 (SEM 0.3) mg kg‐1 h‐1)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Flunitrazepam (total dose 15 (2) micrograms kg‐1 h‐1)
Number of subjects: 16
Study: 2961355

Group type: EXPERIMENTAL
Intervention: Clodronate 1.6 g/day
Number of subjects: 34

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study: 30168759

Group type: EXPERIMENTAL
Intervention: Short femoral stem (MiniHip)
Number of subjects: 53

Group type: COMPARATOR
Intervention: Conventional femoral stem (MetaFix)
Number of subjects: 53
Study: 27923381

Group type: EXPERIMENTAL
Intervention: ARTES (parenteral artesunate at 2.4 mg/kg at H0, H12, H24 and then once daily)
Number of subjects: 0

Group type: COMPARATOR
Intervention: QLD (loading dose of quinine base at 16.6 mg/kg followed 8 h later by an 8-hourly maintenance dose of 8.3 mg/kg quinine base)
Number of subjects: 0

Group type: COMPARATOR
Intervention: QNLD3 (8.3 mg/kg quinine base every 8 h)
Number of subjects: 0

Group type: COMPARATOR
Intervention: QNLD2 (12.5 mg/kg quinine base every 12 h)
Number of subjects: 0
Study: 24946021

Group type: EXPERIMENTAL
Intervention: Naloxegol 25 mg oral dose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Healthy subjects (control group)
Number of subjects: 16